fda compounding semaglutide warning 2025 october New project announcement: HHS‑OIG is taking a closer look at FDA's oversight of compounded GLP‑1 drugs. Although shortages ended in 2025, some facilities may still be producing these drugs at scale. Our Three Considerations When Prescribing Compounded

Plus Gareth remembers that Curacao is both a drink and World Cup finalist, and Ross defends Ghana's football honour

The increases are generally temporary and vary between individuals, but they are one reason GHRP-2 is considered less selective than newer growth hormone secretagogues such as Ipamorelin, which tend to have minimal effects on cortisol and prolactin

doi: 10.2337/DIABETES.51.2007.S434 61 DahlKBrooksAAlmazediFHoffSTBoschiniCBkdalTA

Cell Adhesion and Migration, 11 (4), 384398

Side effects are broadly similar to semaglutide (nausea, constipation, or headache in the early weeks), with one addition specific to tirzepatide some people notice a mild reaction at the injection site

They usually contain ingredients such as caffeine, citrulline, creatine, and beta-alanine